Startups & growth Analysis
ImmunoBiochem is developing antibody-directed protein degraders for autoimmune disease
ImmunoBiochem is developing an autoimmune drug candidate that pairs an antibody with a protein-degrading payload. An earlier oncology licence shows one potential route to commercialization.
